An Extension Protocol for Subjects Who Were Previously Enrolled in Other ARQ 197 Protocols.
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 07 Feb 2018
At a glance
- Drugs Tivantinib (Primary)
- Indications Colorectal cancer; Gastric cancer; Liver cancer; Non-small cell lung cancer; Pancreatic cancer; Renal cancer; Solid tumours
- Focus Therapeutic Use
- Sponsors ArQule
- 31 Jan 2018 Status changed from recruiting to active, no longer recruiting.
- 31 Jan 2018 Planned End Date changed from 1 Dec 2017 to 1 Feb 2019.
- 31 Jan 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Dec 2018.